MarketBeat provided analyst ratings for Alvotech, a company developing a biosimilar to Humira.
3 reports, 2 independent
Updated Sep 19
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat provided analyst ratings for Alvotech, a company developing a biosimilar to Humira.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Alvotech announces development of biosimilar to Humira.1 source
MarketBeat provided analyst ratings for Alvotech, a company developing a biosimilar to Humira.1 source
Keep exploring
The entities involved
-
Alvotech
biotechnology company
Nothing else this week.
-
MarketBeat
American personal finance blog
-
HUMIRA
Czech company
Related events
- MarketBeat uses for analyst ratings and competes in the medical device market, involving Teleflex and Vasamed.
- MarketBeat provided analyst ratings and targets for small-cap healthcare companies Emergent BioSolutions and Entrada Therapeutics.
- MarketBeat aggregated analyst recommendations and price targets for BioMarin Pharmaceutical and Abeona Therapeutics Inc.
- Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
- MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.